Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders, inhibitors |
Mechanism PIP4K2C degraders(phosphatidylinositol-5-phosphate 4-kinase type 2 gamma degraders), PIP4K2C inhibitors(phosphatidylinositol-5-phosphate 4-kinase type 2 gamma inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC44H46N8O11 |
InChIKeyZIZQRWDSILJJFW-UHFFFAOYSA-N |
CAS Registry2794988-39-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 24 Dec 2022 |